Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
Savara Inc. (NASDAQ: SVRA), formerly, Mast Therapeutics (NYSEMKT:MSTX)

Organization & Developments: MAST

Parents

2015: Interview With Brian Culley, CEO Of Mast Therapeutics - Mast Therapeutics, Inc. (NYSEMKT:MSTX)
2016: Mast Therapeutics, Philips Sign Drug Pact (MSTX)
2016: Mast Therapeutics' AIR001 shows positive effect in mid-stage pulmonary hypertension study; shares up 6% - Mast Therapeutics, Inc. (NYSEMKT:MSTX)
2016: Mast Therapeutics’ 84% Crash Led By Disappointing Topline, Results from trial of sickle cell disease drug vepoloxamer (MSTX)
2016: Why Mast Therapeutics Is My Favorite Long For 2016 - Mast Therapeutics, Inc. (NYSEMKT:MSTX)
2019: Here's Why Savara Pharmaceuticals Collapsed Today
2019: Savara: Simple Platform Targeting A Few Rare Diseases_seekingalpha.com
2020: Savara gets FDA breakthrough status despite large, late-stage failure – Endpoints News
2020: Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
2024: Savara: Rolling BLA Submission Of MOLBREEVI Generates Catalysts To Track
Developing AIR001, a sodium nitrite solution for inhalation via nebulizer, for the treatment of heart failure with preserved ejection fraction (HFpEF).
Leveraging the MAST (Molecular Adhesion and Sealant Technology) platform
Mast Therapeutics is developing vepoloxamer, a rheologic polymer, for diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes.